Ramez N. Eskander, MD

Case Overview: High-Risk Ovarian Cancer

Outlook for Patients With High-Risk Ovarian Cancer

Advanced Ovarian Cancer Treatment Strategies

Rucaparib Explored for High-Risk Ovarian Cancer

Rucaparib: Clinical Activity in Relapsed Ovarian Cancer

Rucaparib for Relapsed Ovarian Cancer: Safety Profile

Maintenance Therapy for Advanced Ovarian Cancer

Rucaparib Maintenance Therapy for High-Risk Ovarian Cancer

Future Directions in High-Risk Ovarian Cancer

Case: A 71-Year Old Woman With High-Risk Ovarian Cancer

A 71-year old woman presented to her PCP for a routine annual checkup, she complains of increasing fatigue

2017 diagnosed with stage IV ovarian cancer; 

wt; underwent TAH/BSO, lymph node dissection, with suboptimal debulking; treated with paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab; achieved CR

Chest/abdomen/pelvis CT with contrast shows a suspicious lung lesion

Lung biopsy confirmed recurrent epithelial ovarian cancer

She was started referred to an oncologist and started on carboplatin/doxorubicin, treatment was well tolerated for 4 cycles; CA-125 35 U/mL;

Rucaparib 300 mg BID maintenance was initiated

Chest/abdomen/pelvis CT showed no gross masses or nodes

Videos

Ramez N. Eskander, MD, explains the rationale for treating a 71-year-old woman with ovarian cancer with the PARP inhibitor rucaparib upon relapse.

A 71-Year-Old Woman With High-Risk Ovarian Cancer

A 68-Year-Old Woman With Stage IV Ovarian Cancer

Molecular Testing in Newly Diagnosed Patients

Frontline Therapy Options for Stage IV Ovarian Cancer

GOG-0218 and ICON7 Trial Regimens as Maintenance Therapy

Maintenance Therapy: NCCN Guidelines, PAOLA-1 Trial

Emerging Frontline and I/O PARP Combination Therapies

The Direction of Ovarian Cancer Management

A 68-year-old postmenopausal woman presented with fatigue, urinary frequency, early satiety, abdominal bloating and distention

PMH: HTN, medically treated with lisinopril

SH: retired; grandmother of 3; never-smoker; social alcohol use

PE: abdominal distention, bloating, and a positive fluid wave test; otherwise unremarkable

Pelvic exam with transvaginal ultrasound showed a right ovarian mass

Chest/abdomen/pelvis CT with contrast revealed a right adnexal 5.3-cm complex mass, a suspicious intraparenchymal liver lesion, retroperitoneal lymph node enlargement and concurrent pleural effusion

Lymph node and adnexal mass biopsy confirmed high-grade, epithelial ovarian cancer; positive cytology of pleural effusion

Patient underwent TAH/BSO, lymph node dissection, with suboptimal debulking; residual disease 1.3 cm

Paclitaxel/carboplatin/bevacizumab + maintenance bevacizumab

After 3 cycles, patient underwent second debulking surgery, R0

Continued on bevacizumab for 6 more cycles

Achieved partial response, post treatment CA-125, 40 U/mL
 

Chest/abdomen/pelvis CT showed no gross pelvic masses or nodes

Ramez Eskander, MD, presents the case of a 68-year-old woman with stage IV ovarian cancer, and discusses the management approach for this patient and similar cases. 

Ramez N. Eskander, MD, assistant clinical professor at Moores Cancer Center, discusses the current outlook for the frontline treatment landscape in ovarian cancer.

Eskander says it is an exciting time right now. Many physicians are still using a platinum doublet as first-line treatment for patients with ovarian cancer. However, the approval of bevacizumab (Avastin) has moved this agent to the frontline as well. This is used in combination with maintenance chemotherapy.

More recent data has also led physicians to incorporate olaparib (Lynparza) into the frontline as a maintenance for patients with a germline or somatic

Ramez N. Eskander, MD, discusses the current outlook for the frontline treatment landscape in ovarian cancer.

Ramez N. Eskander, MD | Authors

Articles

A 71-Year-Old Woman With High-Risk Ovarian Cancer

A 68-Year-Old Woman With Stage IV Ovarian Cancer

Examining the Frontline Treatment Landscape for Ovarian Cancer